Monopar Therapeutics Q1 2026 net loss $3.9M; NDA on track for mid-2026

Monopar Therapeutics

Net loss $3.9M ($0.46/share) in Q1 2026 vs $2.6M ($0.38/share) in Q1 2025.
Cash equivalents and investments $137.5M; expects funding through Dec 2027.
NDA for ALXN1840 (Wilson disease) on track for FDA submission in mid-2026.
R&D expenses $3.49M, up $1.84M YoY due to contractor/consulting and personnel.
Presented at AAN; upcoming at EAN (June 27-30) and EASL Congress (May 27-30).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Monopar Therapeutics reported first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $3.9 million, or $0.46 per share, EPS $0.46 per share.

Period: first quarter ended March 31, 2026
Net income: Net loss for the first quarter of 2026 was $3.9 million, or $0.46 per share
EPS: $0.46 per share
Result: reported results

Exact text from the filing

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001437749-26-016981

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.